Using Adalimumab to Treat Autoimmune Enteropathy.

Autoimmune enteropathy is a rare condition seen in adults with limited therapeutic options available. It manifests with profuse diarrhea and malnourishment. The diagnosis is made through a combination of clinical, serologic, and histologic parameters.

Insights into the treatment of inflammatory bowel disease in pregnancy.

Patients diagnosed with inflammatory bowel disease (IBD) are most commonly diagnosed in late adolescence or early adulthood, with half of patients being diagnosed before age 32, thus impacting peak years of reproduction and family planning. While controlled IBD has no negative effects on the ability to conceive, there is overall a trend towards voluntary childlessness due to patients' concerns for adverse fetal outcomes from underlying IBD and from adverse medication effects. Active disease at the time of conception is associated with worsening disease activity during pregnancy and carries a higher risk of poor fetal outcomes.

Immunosuppressive therapies for inflammatory bowel disease.

Inflammatory bowel disease (IBD) is comprised of Crohn's disease and ulcerative colitis, both chronic inflammatory intestinal disorders of unknown etiology characterized by a waxing and waning clinical course. For many years, the drug therapy was limited to sulfasalazine and related aminosalicylates, corticosteroids and antibiotics. Studies suggesting that the pathophysiology of these disorders relates to a disregulated, over-active immune response to indigenous bacteria have led to the increasing importance of immunosuppressive drugs for the therapy of IBD.

A review of autopsy reports on chimpanzees in or from US laboratories.

Approximately 1000 chimpanzees are currently held in five federally owned, or supported, US laboratories. This study reviews 110 autopsy reports on chimpanzees who died from 2001-2011 in laboratories or in sanctuaries (but who were from laboratories), in order to glean information about their premorbid health and causes of death. The findings raise questions about the health status of the chimpanzees remaining in laboratories.

Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy.

Background: An abdominal phlegmon is an inflammatory mass that can develop in the setting of penetrating Crohn's disease (CD). Anti-tumor necrosis factor (TNF) antibody therapy is typically avoided in CD complicated by phlegmon because of concern for peritoneal infection but may offer an effective alternative to surgical resection after infection has been controlled with antibiotics. The aim of this study was to examine outcomes for patients with CD who developed an abdominal phlegmon that was subsequently treated with an anti-TNF antibody.